[Form 4] Cidara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. (CDTX) – Form 4 Insider Transaction

The filing discloses a single transaction by director Chrysa Mineo on 18 June 2025. Ms. Mineo received a non-cash grant of 11,100 stock options with an exercise price of $21.31 per share. These options vest in full on the earlier of (i) 18 June 2026 or (ii) the day prior to the company’s 2026 annual shareholders’ meeting, and they expire on 17 June 2035.

The filing shows no open-market purchases or sales of common stock; the only position reported is the newly issued derivative security. Post-grant, Ms. Mineo beneficially owns 11,100 options, recorded as direct (D) ownership. No indirect holdings or additional equity awards are listed.

Because the transaction is a routine director equity award and does not involve the purchase or sale of currently outstanding shares, the filing does not directly affect the public float, cash flow, or near-term earnings. From a governance standpoint, it aligns director incentives with shareholder interests but is not expected to be financially material to CDTX given the company’s share count and market capitalization.

Insights

Securities Analyst

TL;DR: Routine option grant to director; no cash exchanged; neutral for valuation.

This Form 4 documents a standard board compensation action—11,100 options granted at $21.31. The award vests in roughly one year and expires in 2035, indicating long-term alignment. No common shares were bought or sold, so there is no immediate supply-demand impact. Given Cidara’s typical option practices and the limited size of the grant relative to shares outstanding, I deem the filing informational rather than valuation-moving. Investors should simply record the new fully-diluted share potential.

Corporate Governance Expert

TL;DR: Standard equity incentive; supports alignment, but immaterial to governance risk profile.

The award follows typical director compensation frameworks—one-year vest, ten-year term, direct ownership. There are no 10b5-1 plan indications and no red-flag transactions. The expiration well beyond strategic planning horizons ensures alignment without near-term dilution pressure. Overall governance implications are neutral; nothing in the disclosure suggests heightened oversight concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mineo Chrysa

(Last) (First) (Middle)

C/O CIDARA THERAPEUTICS, INC.

6310 NANCY RIDGE DRIVE SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.31	06/18/2025		A		11,100		(1)	06/17/2035	Common Stock	11,100	$0	11,100	D

Explanation of Responses:

1. The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cidara Therapeutics (CDTX) disclose in the latest Form 4?

The company reported a grant of 11,100 stock options to director Chrysa Mineo on 18 June 2025.

What is the exercise price of the options granted to Chrysa Mineo?

The options carry an exercise price of $21.31 per share.

When do the newly granted CDTX options vest and expire?

They vest on 18 June 2026 (or prior to the 2026 annual meeting) and expire on 17 June 2035.

Did the Form 4 include any open-market purchases or sales of CDTX common stock?

No. The filing reports only the non-cash option grant; no common shares were bought or sold.

How many derivative securities does the director own after this transaction?

Following the grant, Ms. Mineo beneficially owns 11,100 stock options.